Should the Non-Canonical NO Pathway be Targeted in Hypertensive Pregnancies?
Elizabeth C CottrellPublished in: British journal of pharmacology (2023)
Hypertension in pregnancy is prevalent, affecting around 10% of pregnancies worldwide, and significantly increases the risk of adverse outcomes for both mothers and their babies. Current treatment strategies for pregnant women with hypertension are limited and new approaches for the management of hypertension in pregnancy are urgently needed. Substantial evidence from non-pregnant subjects has demonstrated the potential for dietary nitrate supplementation to increase nitric oxide (NO) bioavailability and lower blood pressure, following bioactivation via the non-canonical NO pathway. Emerging data suggests this approach may also be of benefit in pregnant women, although studies are limited. This review aims to summarise the current evidence from preclinical and clinical studies of nitrate supplementation in pregnancy, drawing on data from non-pregnant populations where appropriate, and highlighting key gaps in knowledge that remain to be addressed in future trials.
Keyphrases
- blood pressure
- pregnant women
- pregnancy outcomes
- nitric oxide
- preterm birth
- hypertensive patients
- heart rate
- gestational age
- electronic health record
- big data
- healthcare
- stem cells
- nitric oxide synthase
- type diabetes
- metabolic syndrome
- artificial intelligence
- machine learning
- weight loss
- climate change
- deep learning
- human health
- genetic diversity
- glycemic control